Profile of perampanel and its potential in the treatment of partial onset seizures
Neuropsychiatric Disease and Treatment · 2013-05 · 629
DOI: 10.2147/ndt.s30129 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropsychiatric Disease and Treatment, 2013-05. Verfasst von Sylvain Rheims und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Functional Neurology and Epileptology and Institute for Children and Adolescent with Epilepsy, Hospices Civils de Lyon, Lyon, France ; …. Die Arbeit wurde bisher 20-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Perampanel (PER) is a novel antiepileptic compound that decreases neuronal excitability by modulating glutamatergic transmission through selective noncompetitive blockade of AMPA receptors. PER has been evaluated in three pivotal placebo-controlled randomized trials as adjunctive therapy in adult drug-resistant partial epilepsy. In comparison to placebo, adjunctive PER effectively reduces seizure frequency. The relative risk of the responder rate (95% confidence interval [CI]) was thus 1.60 (1.08-2.36), 1.79 (1.42-2.25) and 1.66 (1.24-2.23) for once-daily PER 4 mg/day, 8 mg/day and 12 mg/day, respectively. The most common adverse events associated with PER were nonspecific central nervous system side effects. Some concerns have been raised about risk of clinically significant weight gain and of psychiatric adverse events. Long-term open-label extensions of the three pivotal trials are underway. PER has recently been approved both in Europe and in the USA for the adjunctive treatment of partial onset seizures in patients aged 12 years and above. However, in the absence of a direct comparison between PER and other licensed antiepileptic drugs' efficacy and tolerability, the clinical advantages of PER over the other drugs in intractable partial epilepsy remains to be determined.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Functional Neurology and Epileptology and Institute for Children and Adolescent with Epilepsy, Hospices Civils de Lyon, Lyon, France ; Lyon Neuroscience Research Center, INSERM U1028/CNRS UMR 5292 Translat…
Zitieren
APA
Rheims, S., & Ryvlin, P. (2013). Profile of perampanel and its potential in the treatment of partial onset seizures. Neuropsychiatric Disease and Treatment, 629. https://doi.org/10.2147/ndt.s30129
Vancouver
Rheims S, Ryvlin P. Profile of perampanel and its potential in the treatment of partial onset seizures. Neuropsychiatric Disease and Treatment. 2013:629. doi:10.2147/ndt.s30129
BibTeX
@article{Rheims2013,
author = {Rheims, Sylvain and Ryvlin, Philippe},
title = {Profile of perampanel and its potential in the treatment of partial onset seizures},
journal = {Neuropsychiatric Disease and Treatment},
year = {2013},
pages = {629},
doi = {10.2147/ndt.s30129}
}
EUVIMED